Acromegaly
Conditions
Brief summary
The purpose of this study is to evaluate the effectiveness in IGF-1 control of lanreotide Autogel (ATG) 120 mg at extended dosing intervals (EDIs) (\>4 weeks) in subjects with acromegaly in daily clinical practice.
Interventions
None listed
Sponsors
Ipsen
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men or women aged ≥ 18 years * Diagnosed with acromegaly * Receiving treatment with ATG 120 mg at extended dosing intervals (\> 4 weeks) for at least six months before the study visit. * Assay data (blood GH and IGF-1 levels) from immediately before the study visit (performed at least six months after starting the treatment) is available. * Able to sign the informed consent form for study participation.
Exclusion criteria
* Received radiation therapy treatment in the last six months. * Active participation in another clinical study. * Physical or mental disorders that, in the investigator's opinion, could affect their ability to sign the informed consent form. * Pregnancy or breastfeeding for female patients. * No data in their medical records on the treatment start date for ATG 120 mg at extended dosing intervals or on changes to the schedule of administration over the last six months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of subjects with a normal Insulin-like Growth Factor 1 (IGF-1) level in the assay before the study visit. | Day 1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of subjects treated with lanreotide autogel (ATG) 120 mg for ≥ 6 months with dosing intervals of five, six, seven or eight weeks. | Day 1 | — |
| Percentage of subjects whose dosing regimen has been changed in the six months before the study. | Day 1 | — |
| Preference for self-administered injections or administration in an outpatient clinic by a medical professional. | Day 1 | — |
| Percentage of subjects with Growth hormone (GH) levels ≤ 2.5 ng/mL or ≤ 1 ng/mL in the assay before the study visit. | Day 1 | — |
| EuroQol-5D (EQ-5D) questionnaire in subjects after ≥ 5 months of treatment with ATG 120 mg at extended dosing intervals. | Day 1 | Total score and score per domain |
| Treatment Satisfaction Questionnaire for Medication-9 (TSMQ-9) in subjects treated with ATG 120 mg at extended dosing intervals after ≥ 5 months. | Day 1 | Total score and score per domain |
| Variations between theoretical and real treatment compliance for non-medical reasons. | Day 1 | — |
| Acromegaly Quality of Life Questionnaire (AcroQoL) in subjects after ≥ 5 months of treatment with ATG 120 mg at extended dosing intervals. | Day 1 | Total score and score per domain |
Countries
Portugal, Spain
Outcome results
None listed